Riskpilot← Back to searchSign inGet full accessGHN Pharma Metabolic AB
ABActiveOrg 5592767601Flöjelbergsgatan 12Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20200 employees
Revenue 2024
SEK 5,1M
+23% vs 2023
EBITDA margin
31.8%
+94% vs 2023
Equity ratio
80.4%
Financial strength
Net profit 2024
SEK 1,3M
+94% vs 2023
| Revenue | SEK 5,1M | +23% |
| EBITDA | SEK 1,6M | +94% |
| Net profit | SEK 1,3M | +94% |
| Total assets | SEK 2,1M | +38% |
| Equity | SEK 1,6M | +73% |
| Employees | 0 | — |
Legal name
GHN Pharma Metabolic AB
Org number
5592767601
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
14 oktober 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva handel, marknadsföring, distribution och utveckling av produkter inom läkemedel och hälso- och sjukvård samt därmed förenlig verksamhet. Bolaget ska även ha som verksamhet att äga och förvalta fast och lös egendom.
Address
Flöjelbergsgatan 12
Email
roland@ghnpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 324 | 2 509 | 4 183 | 5 145 |
| Staff expenses | — | — | — | — |
| EBITDA | 57 | 1 029 | 842 | 1 636 |
| Depreciation & amort. | −0 | −0 | −0 | −0 |
| EBIT | 57 | 1 029 | 842 | 1 636 |
| Net financials | — | — | — | — |
| Profit before tax | 57 | 1 029 | 842 | 1 635 |
| Tax | −12 | −213 | −175 | −340 |
| Net profit | 45 | 816 | 667 | 1 295 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 343 | 1 288 | 1 482 | 2 051 |
| Equity | 70 | 886 | 953 | 1 648 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 273 | 402 | 529 | 402 |
| Total debt | 273 | 402 | 529 | 402 |
EBITDA margin
31.8%
This company
15.8%
Market median
+101% vs market
20212024
Equity ratio
80.4%
This company
38.2%
Market median
+110% vs market
20212024
Return on equity
78.6%
This company
18.4%
Market median
+327% vs market
20212024
Net profit margin
25.2%
This company
8.1%
Market median
+211% vs market
20212024
Asset turnover
2.51×
This company
1.12×
Market median
+124% vs market
20212024
Debt / equity
0.24×
This company
0.62×
Market median
+61% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-10-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
VH Chief Executive Officer | Chief Executive Officer | 2022 |
KI Chief Auditor | Chief Auditor | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Former (2) | ||
| Board of Directors | 2020 – 2022 | |
| Deputy Board Member | 2020 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
GHN Pharma AB
GHN Pharma Metabolic AB Board members of GHN Pharma Metabolic AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Valdet Hetemi | Chief Executive Officer | 0 companies |
| Kristofer Ingmar Håkansson | Chief Auditor | 0 companies |
| Tina Madsen Sandström | Chairman | 0 companies |
| Bengt Roland Sandström | Board of Directors | 0 companies |
| Nils Pontus Larsson Bergman | Board of Directors | 0 companies |
| Kjell Martin Svahn | Board of Directors | 0 companies |
| Tuva Clara Maria Vamborg | Deputy Board Member | 0 companies |